Vorapaxar
- Generic Name
- Vorapaxar
- Brand Names
- Zontivity
- Drug Type
- Small Molecule
- Chemical Formula
- C29H33FN2O4
- CAS Number
- 618385-01-6
- Unique Ingredient Identifier
- ZCE93644N2
- Background
Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents t...
- Indication
Vorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). It is usually co-administered with acetylsalicylic acid (ASA) and/or clopidogrel, and should therefore be administered as an addition to these medications as it has not been studied alone.
- Associated Conditions
- Cardiovascular Events
- Associated Therapies
- -
Vorapaxar on Thrombin Generation and Coagulability
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Inova Health Care Services
- Target Recruit Count
- 81
- Registration Number
- NCT03207451
- Locations
- 🇺🇸
Inova Fairfax Hospital, Falls Church, Virginia, United States
Vorapaxar and Lower Extremity Bypass Grafts
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Vanderbilt University
- Registration Number
- NCT02975583
Vorapaxar in the Human Endotoxemia Model
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 16
- Registration Number
- NCT02875028
- Locations
- 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 66
- Registration Number
- NCT02548650
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor
- Conditions
- Interventions
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 130
- Registration Number
- NCT02545933
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 65
- Registration Number
- NCT02394730
- Locations
- 🇺🇸
Georgetown University Hospital, Georgetown, Maryland, United States
🇦🇺Melbourne Sexual Health Centre, Carlton, Victoria, Australia
🇺🇸Hennepin County Medical Centre, Minneapolis, Minnesota, United States
Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)
- Conditions
- Interventions
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT00684203
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)
- Conditions
- Interventions
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12944
- Registration Number
- NCT00527943
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
- Conditions
- Interventions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 26449
- Registration Number
- NCT00526474
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.